Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Monsanto Company has signed an exclusive licensing agreement with Marina Biotech for delivery and chemistry technologies.
Subscribe to our email newsletter
The companies kept the terms of the agreement confidential.
Marina Biotech president and chief executive officer Michael French said, "We view this license as yet another important validation of this platform and we look forward to a strong and growing relationship with Monsanto."
Marina Biotech is focused on the development and commercialization of oligonucleotide-based therapeutics utilizing multiple mechanisms of action including RNA interference (RNAi) and messenger RNA translational blocking.